FR20C1054I1 - Derives de quinolines et compositions pharmaceutiques de ces derives - Google Patents

Derives de quinolines et compositions pharmaceutiques de ces derives

Info

Publication number
FR20C1054I1
FR20C1054I1 FR20C1054C FR20C1054C FR20C1054I1 FR 20C1054 I1 FR20C1054 I1 FR 20C1054I1 FR 20C1054 C FR20C1054 C FR 20C1054C FR 20C1054 C FR20C1054 C FR 20C1054C FR 20C1054 I1 FR20C1054 I1 FR 20C1054I1
Authority
FR
France
Prior art keywords
derivatives
pharmaceutical compositions
quinoline
quinoline derivatives
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1054C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613159A external-priority patent/GB0613159D0/en
Priority claimed from GB0613158A external-priority patent/GB0613158D0/en
Priority claimed from GB0613156A external-priority patent/GB0613156D0/en
Priority claimed from GB0613160A external-priority patent/GB0613160D0/en
Priority claimed from EP06117129A external-priority patent/EP1878722A1/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR20C1054I1 publication Critical patent/FR20C1054I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR20C1054C 2006-06-30 2020-11-12 Derives de quinolines et compositions pharmaceutiques de ces derives Active FR20C1054I1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0613159A GB0613159D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613158A GB0613158D0 (en) 2006-06-30 2006-06-30 Organic compounds
GB0613156A GB0613156D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613160A GB0613160D0 (en) 2006-06-30 2006-06-30 Organic Compounds
EP06117129A EP1878722A1 (en) 2006-07-13 2006-07-13 Quinolinone derivatives and their pharmaceutical compositions
EP07819899A EP2044025B1 (en) 2006-06-30 2007-07-02 Quinolinone derivatives and their pharmaceutical compositions

Publications (1)

Publication Number Publication Date
FR20C1054I1 true FR20C1054I1 (fr) 2020-12-25

Family

ID=38610531

Family Applications (2)

Application Number Title Priority Date Filing Date
FR20C1054C Active FR20C1054I1 (fr) 2006-06-30 2020-11-12 Derives de quinolines et compositions pharmaceutiques de ces derives
FR20C1063C Active FR20C1063I1 (fr) 2006-06-30 2020-12-08 Derives de quinolines et compositions pharmaceutiques de ces derives

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR20C1063C Active FR20C1063I1 (fr) 2006-06-30 2020-12-08 Derives de quinolines et compositions pharmaceutiques de ces derives

Country Status (28)

Country Link
US (2) US8198450B2 (xx)
EP (1) EP2044025B1 (xx)
JP (1) JP5253392B2 (xx)
KR (1) KR101402398B1 (xx)
CN (1) CN101479245B (xx)
AU (1) AU2007264946B2 (xx)
BR (1) BRPI0713951B8 (xx)
CA (1) CA2654801C (xx)
CY (3) CY1113733T1 (xx)
DK (1) DK2044025T3 (xx)
ES (1) ES2396987T3 (xx)
FR (2) FR20C1054I1 (xx)
HK (1) HK1127597A1 (xx)
HR (1) HRP20121074T1 (xx)
HU (2) HUS2000043I1 (xx)
IL (1) IL195796A (xx)
LT (2) LTC2044025I2 (xx)
LU (2) LUC00185I2 (xx)
MA (1) MA30540B1 (xx)
MX (1) MX2008016542A (xx)
MY (1) MY150468A (xx)
NO (3) NO341709B1 (xx)
NZ (1) NZ573292A (xx)
PL (1) PL2044025T3 (xx)
PT (1) PT2044025E (xx)
SI (1) SI2044025T1 (xx)
WO (1) WO2008000839A1 (xx)
ZA (1) ZA200809948B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500738A (ja) 1996-09-17 2001-01-23 カイロン コーポレイション 細胞内疾患を処置するための組成物および方法
AU2008294473B2 (en) 2007-09-05 2013-12-05 Rigel Pharmaceuticals, Inc. Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one) -6-yl]-5-fluoro-N2-[3-methylaminocar-bonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
AU2014229361B2 (en) 2013-03-14 2016-08-04 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
WO2017055506A1 (en) 2015-09-29 2017-04-06 Laboratorios Lesvi, S.L. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl] -8-hydroxy-1h-quinolin-2-one l-tartrate
CN110724095B (zh) * 2019-09-12 2023-06-09 上海方予健康医药科技有限公司 一种茚达特罗乙酸盐的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05202301A (ja) * 1991-08-29 1993-08-10 Yamamoto Chem Inc ２−アニリノ−３−メチル−６−（Ｎ−ｎ−ブチル−Ｎ−シクロヘキシルアミノ）フルオランの結晶変態、その製造方法及びこの結晶変態を含有する記録材料
EP0688871A3 (en) * 1994-06-24 1998-07-08 Quest International B.V. Preparation of phytosphingosine derivative
FR2777279B1 (fr) * 1998-04-08 2004-08-13 Hoechst Marion Roussel Inc Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
US7417051B2 (en) 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
TWI324150B (en) 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20100399A1 (es) 2003-04-02 2010-06-01 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
JP4516064B2 (ja) * 2003-04-04 2010-08-04 ノバルティス アーゲー 気道疾患の処置のためのキノリン−２−オン誘導体
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
CN101142217B (zh) 2005-03-21 2010-12-08 伊莱利利公司 咪唑并哒嗪化合物
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors

Also Published As

Publication number Publication date
LUC00188I2 (xx) 2024-07-01
BRPI0713951B1 (pt) 2019-08-13
IL195796A0 (en) 2009-09-01
HUS2000053I1 (hu) 2020-12-28
NO20090312L (no) 2009-01-28
AU2007264946A1 (en) 2008-01-03
BRPI0713951B8 (pt) 2021-05-25
CY1113733T1 (el) 2016-06-22
PL2044025T3 (pl) 2013-02-28
CY2020038I2 (el) 2021-03-12
US20120316142A1 (en) 2012-12-13
DK2044025T3 (da) 2013-01-14
CA2654801C (en) 2014-08-19
US8198450B2 (en) 2012-06-12
KR20090023651A (ko) 2009-03-05
CY2020041I2 (el) 2021-03-12
HUS2000043I1 (hu) 2020-12-28
NO2020041I1 (no) 2020-11-23
EP2044025B1 (en) 2012-10-03
KR101402398B1 (ko) 2014-06-03
CY2020038I1 (el) 2021-03-12
NO2020044I1 (no) 2020-12-07
MX2008016542A (es) 2009-01-19
JP2009541455A (ja) 2009-11-26
IL195796A (en) 2016-03-31
US20090325912A1 (en) 2009-12-31
LTPA2020535I1 (lt) 2020-12-28
ES2396987T3 (es) 2013-03-01
PT2044025E (pt) 2012-12-17
AU2007264946B2 (en) 2011-01-20
ZA200809948B (en) 2009-05-25
MY150468A (en) 2014-01-30
FR20C1063I1 (fr) 2021-01-22
EP2044025A1 (en) 2009-04-08
JP5253392B2 (ja) 2013-07-31
SI2044025T1 (sl) 2013-01-31
CN101479245A (zh) 2009-07-08
LTC2044025I2 (lt) 2022-10-10
CA2654801A1 (en) 2008-01-03
NZ573292A (en) 2011-03-31
NO341709B1 (no) 2018-01-02
MA30540B1 (fr) 2009-06-01
BRPI0713951A2 (pt) 2012-12-04
LTPA2020538I1 (lt) 2021-01-11
CY2020041I1 (el) 2021-03-12
HK1127597A1 (en) 2009-10-02
HRP20121074T1 (hr) 2013-01-31
LUC00185I2 (xx) 2024-07-01
WO2008000839A1 (en) 2008-01-03
CN101479245B (zh) 2013-05-22

Similar Documents

Publication Publication Date Title
FR20C1063I1 (fr) Derives de quinolines et compositions pharmaceutiques de ces derives
IL199853A (en) Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
BRPI0923836A2 (pt) Composições farmacêuticas orais contendo opióide e métodos
BRPI0906980A2 (pt) Composição de derivados e maleatados
SMT201700084B (it) Associazioni antineoplastiche di 4-anilino-3-cianochinoline e capecitabina
DE602007010981D1 (de) Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
BRPI0918759A2 (pt) ácidos 2-aril-propiônicos e derivados e composições farmacêuticas contendo os mesmos
CR10815A (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
EP2188259A4 (en) PROCESS FOR THE PREPARATION AND ADMINISTRATION OF CHINOLINE DERIVATIVES AS ANTICROBIAL AGENTS
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
BRPI1007092A2 (pt) "derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas, método para prevenção ou tratamento de doença e método de produção de derivados de hidroxamato"
IL193211A (en) Derivatives of Indzol-Troaril and pharmaceutical preparations containing them
BRPI0813100A2 (pt) Preparação sólida farmacêutica e método de produção da mesma
ATE467619T1 (de) Antibakterielle chinolinderivate
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
ATE499368T1 (de) Chinolonverbindung und pharmazeutische zusammensetzung
BRPI0819202A2 (pt) Derivado heterocíclico, e, composição farmacêutica
UY33128A (es) Derivados de piridinona y composiciones farmacéuticas de los mismos
ZA200806725B (en) New citrate salt of an indole derivative and its pharmaceutical use
SI2220047T1 (sl) Derivati kinolina, farmacevtski sestavki, ki jih vsebujejo in njihova uporaba
BRPI0812832A2 (pt) Combinação farmacêutica de opioides e composto de prostaglandina
TH0801002797A (th) สารประกอบควินอโลน และองค์ประกอบทางเภสัชกรรม